Avanafil is a PDE5 inhibitor approved for erectile dysfunction by FDA on April 27 2012 and by EMA on June 21 2013. Avanafil is known by the trademark names Stendra and Spedra and was developed by Vivus Inc. In July 2013 Vivus announced partnership with Menarini Group which will commercialise and promote Spedra in over 40 European countries plus Australia and New Zealand.
This page contains content from the copyrighted Wikipedia article "Avanafil"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
